Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21073Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Giatromanolaki, A. | en |
| dc.contributor.author | Bai, M. | en |
| dc.contributor.author | Margaritis, D. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Koukourakis, M. I. | en |
| dc.contributor.author | Sivridis, E. | en |
| dc.contributor.author | Gatter, K. C. | en |
| dc.date.accessioned | 2015-11-24T19:12:27Z | - |
| dc.date.available | 2015-11-24T19:12:27Z | - |
| dc.identifier.issn | 1791-7530 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21073 | - |
| dc.rights | Default Licence | - |
| dc.subject | Basic Helix-Loop-Helix Transcription Factors/metabolism | en |
| dc.subject | Cell Hypoxia/physiology | en |
| dc.subject | Humans | en |
| dc.subject | Hypoxia-Inducible Factor 1, alpha Subunit/metabolism | en |
| dc.subject | Immunohistochemistry | en |
| dc.subject | Multiple Myeloma/blood supply/*metabolism/pathology | en |
| dc.subject | Neovascularization, Pathologic/metabolism/pathology | en |
| dc.subject | Phosphorylation | en |
| dc.subject | Receptors, Vascular Endothelial Growth Factor/*metabolism | en |
| dc.subject | Vascular Endothelial Growth Factor A/*metabolism | en |
| dc.subject | Vascular Endothelial Growth Factor Receptor-2/metabolism | en |
| dc.title | Hypoxia and activated VEGF/receptor pathway in multiple myeloma | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20683019 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | BACKGROUND/AIM: Intensified angiogenic pathways are associated with poor prognosis and resistance of multiple myeloma (MM) cells to therapy. The links of the VEGF pathway with the hypoxia inducible factor (HIF) expression in MM are herein investigated. MATERIALS AND METHODS: The vascular density (VD) and the HIF/VEGF/VEGF-receptor expression in the bone marrows of 106 MM cases were studied using immunohistochemistry. RESULTS: HIF1alpha and HIF2alpha were expressed strongly in 33% and 13.2% of the cases, respectively. VEGFR and the phosphorylated (active) form of VEGFR2/KDR receptors were up-regulated in 42.5% and 36.8% of cases, respectively. Both HIF1alpha and HIF2alpha were significantly linked with high VD and VEGF expression. Moreover, the expression of the phosphorylated (active) form of VEGFR2/KDR was significantly linked with VEGF and HIF1alpha expression. The HIF/VEGF/VEGF-receptor pathway is up-regulated in approximately 40% of MM cases and linked with increased angiogenesis. Survival analysis in 37 evaluable patients showed a significantly worse prognosis in cases with high VD. CONCLUSION: HIFs and VEGF are up-regulated in a significant percentage of MM and are strongly related to each other. Targeting HIFs and the VEGF/receptor autocrine loop may prove of importance in the treatment of the disease. | en |
| heal.journalName | Anticancer Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
